US General Anesthesia Drugs Market

US General Anesthesia Drugs Market by Route of Administration (Intravenous and Inhalational), End User (Hospitals, Ambulatory Surgery Centers) - Forecast to 2025

Report Code: PH 1174 Feb, 2021, by marketsandmarkets.com

[118 Pages Report] The US general anesthesia drugs market size is projected to reach USD 2.4 billion by 2025 from USD 2.0 billion in 2020, at a CAGR of 3.4% during the forecast period. The rising prevalence of cancer, rapid growth in geriatric population, and increasing number of emergency surgeries are some of the major factors driving the growth of the US general anesthesia drugs.

US General Anesthesia Drugs Market

To know about the assumptions considered for the study, Request for Free Sample Report

Covid-19 Impact On The  US General Anesthesia Drugs Market

The COVID-19 pandemic has significantly affected the anesthesia drugs market. The general anesthesia drugs sector is witnessing challenges in the manufacturing and supply chain, such as delivering products to end users on time and attending to an uneven demand for products.

The market for general anesthesia drugs is witnessing short-term negative growth. It can be attributed to factors such as the decline in the product demand from major end users, limited surgeries in most hospitals, and disrupted supply chain and challenges in terms of providing essential services due to lockdowns.\

Non-essential surgical procedures were placed on hold as an initial response to prepare for an impending surge in COVID-19–related inpatient hospital stays and to mitigate the potential spread of the virus within health care facilities. The reduction in non-essential surgeries lead to reduced demand for surgical anesthesia. However, hospitals have faced an unprecedented surge in intensive care unit (ICU) patients during the COVID-19 pandemic. As per studies, around 5–10% of COVID-19 patients require prolonged intensive care for acute respiratory distress syndrome (ARDS). These patients tend to require high doses of sedatives and paralytics, which subsequently led to an increased demand for critical care drugs, including anesthesia drugs, paralytics, opioids, and vasoactive agents, especially to support ventilatory strategies for ARDS. Due to this, the effect of COVID-19 on the anesthesia drugs market has been less severe.

US General Anesthesia Drugs Market Dynamics

Driver:Rising prevalence of cancer

The prevalence of cancer has increased significantly in the US over the last few decades. According to the National Cancer Institute, as of January 2019, there were an estimated 16.9 million cancer survivors in the US. The number of cancer survivors is projected to increase to 22.2 million by 2030. The most common cancers (listed in descending order according to estimated new cases in 2020) are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. Prostate, lung, and colorectal cancers accounted for 43% of all cancers diagnosed in men in 2020. Whereas, in women, breast, lung, and colorectal cancer accounted for over 50% of all new cancers diagnosed in 2020. The rising prevalence of cancer will lead to a rise in the number of surgeries as for many tumors, cancer surgery is the best chance for a cure, especially if the cancer is localized. Thus, the growing prevalence of cancer will fuel the growth of the US general anesthesia market, as general anesthesia is commonly used for surgical procedures to treat cancer.

Restraints: Risks associated with general anesthesia in pediatric patients and pregnant women

The use of pharmacologic agents, including general anesthesia drugs, in pediatric patients, warrants special considerations. In comparison to adults, infants and young children respond differently to anesthesia medications due to many factors, including body composition, protein binding, body temperature, distribution of cardiac output, and functional maturity of the liver and kidneys.

According to various studies, the use of general anesthetics and sedation drugs in pregnant animals and young animals for more than 3 hours caused widespread loss of nerve cells in the brain. Recent human studies suggest that a single, relatively short exposure to general anesthetics and sedation drugs in infants or toddlers is unlikely to have negative effects on behavior or learning.

In view of the same, the US FDA issued new warnings in April 2017, related to the use of general anesthetics and sedation drugs in young children and pregnant women. General anesthetics and sedation drugs are necessary for patients, including young children and pregnant women, who require surgery or other painful and stressful procedures. The US FDA has warned about the repeated or lengthy use of general anesthetics and sedation drugs during surgeries or procedures in children younger than three years and pregnant women. The potential risk associated with the use of general anesthesia drugs in young children and pregnant women can lead to a decrease in the uptake of general anesthetics by healthcare professionals and thus may hinder market growth

Opportunity: Patent expiry of Lusedra

Lusedra (fospropofol disodium) is an intravenous sedative-hypnotic agent. It was approved by the FDA in 2008 for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures. This molecule will go off-patent by 2022. The patent expiration of this molecule will pave the way for generic drugs to enter the US market, which is expected to offer a significant growth outlook for the key players operating in the US general anesthesia drugs market.

By Route of Administration, the intravenous drugs segment accounted for the largest share of the US general anesthesia drugs market

The intravenous drugs segment is expected to account for the largest market share in 2020. General intravenous anesthesia drugs are less expensive and do not require expensive machines for administration. Moreover, intravenous anesthesia drugs results in less cardiovascular depression and provide better postoperative analgesia. These factors are expected to propel the growth of this segment during the forecast period.

By End user, Hospitals accounted for the largest share of the US general anesthesia drugs market

Hospitals dominated the US general anesthesia drugs market in 2020. Growth in this market segment can largely be attributed to the massive patient footfall in hospitals and the increasing number of surgeries performed in these facilities.

Some of the key players include Baxter International Inc. (US), Hikma Pharmaceuticals plc (UK), Pfizer Inc. (US), Piramal Enterprises Limited (India), AbbVie (US), Fresenius SE & Co. KGaA (Germany), Par Pharmaceutical (US), Teva Pharmaceuticals (Israel), Viatris/Mylan (US), Novartis AG (US), Abbott Laboratories (US), AstraZeneca plc (US), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (UK), Gilead Sciences, Inc. (US), Bayer AG (Germany), Merck & Co., Inc. (Germany), Sanofi (France), Heritage Pharmaceuticals Inc. (US), Akorn (US), and Apotex (Canada).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market Size Available for Years

2016–2025

Base Year Considered

2019

Forecast Period

2020–2025

Forecast Units

Value (USD Billion)

Segments Covered

Route of Administration, End User

Geographies Covered

US

Companies Covered

The US general anesthesia drugs market is dominated by a few  established players such as Baxter International Inc. (US), Hikma Pharmaceuticals plc (UK), Pfizer Inc. (US), Piramal Enterprises Limited (India), AbbVie (US), Fresenius SE & Co. KGaA (Germany), Par Pharmaceutical (US), Teva Pharmaceuticals (Israel), Viatris/Mylan (US), Novartis AG (US), Abbott Laboratories (US), AstraZeneca plc (US), F.Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (UK), Gilead Sciences, Inc. (US), Bayer AG (Germany), Merck & Co., Inc. (Germany), Sanofi (France), Heritage Pharmaceuticals Inc. (US), Akorn (US), and Apotex (Canada). (Total 20 Companies)

The study categorizes the US general anesthesia drugs market into the following segments and subsegments:

  • By Route of Administration
    • Inhalational
      • Sevoflurane
      • Desflurane
      • Isoflurane
      • Nitrous Oxide
    • Intravenous
      • Propofol
      • Benzodiazepines
      • Ketamine
      • Methohexital Sodium
      • Others (Etomidate, Fentanyl, Remifentanil)
  • By End User
    • Hospitals
    • Ambulatory Surgery Centers
  • Company Type
    • Tier 1 Pharmaceutical Companies
    • Tier 2 Pharmaceutical Companies
    • Tier 3 Pharmaceutical Companies

Recent Developments

  • In 2020, Fresenius Kabi introduced its first medications with smart labels embedded with radio-frequency identification technology. The first RFID smart-labeled product, Diprivan (Propofol) 200 mg per 20 mL (10 mg per mL) Injectable Emulsion, USP, was introduced in the US
  • In 2020, Hikma Pharmaceuticals USA Inc. launched the Propofol Injectable Emulsion, USP, 20 mL, 50 mL, and 100 mL vials in the US
  • In 2020, AbbVie acquired Allergan to expand its product offerings in key therapeutic areas, including oncology, neuroscience, and anesthetics.
  • In 2020, Novartis AG acquired Aspen’s Japanese operations focused on generics and off-patent medicines.

Frequently Asked Questions (FAQs)

Key Questions Addressed in the Report:

  • Which type of anesthesia drugs has the largest share in the market?
  • In 2019, the intravenous anesthesia drugs segment accounted for the largest share of the US general anesthesia drugs market.
  • Which intravenous anesthesia drug holds the largest market share in the US general anesthesia drugs market?
  • Propofol accounted for the largest market share in 2019. Some of the factors such as rapid loss of consciousness, quick recovery from propofol-induced anesthesia and frequent side effects (e.g., drowsiness, nausea, and vomiting) compared to other agents is responsible for market growth of propofol

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 16)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
    1.3 MARKET SCOPE
           1.3.1 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 19)
    2.1 RESEARCH DATA
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                 FIGURE 1 BREAKDOWN OF PRIMARIES: US GENERAL ANESTHESIA DRUGS MARKET
           2.1.3 MARKET DATA ESTIMATION & TRIANGULATION
                 FIGURE 2 DATA TRIANGULATION METHODOLOGY
    2.2 MARKET ESTIMATION METHODOLOGY
        FIGURE 3 MARKET SIZE ESTIMATION (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)
        FIGURE 4 US GENERAL ANESTHESIA DRUGS MARKET SIZE (USD MILLION)
        FIGURE 5 US GENERAL ANESTHESIA DRUGS MARKET: GROWTH RATE OF TOP COMPANIES (2018−2019)
        FIGURE 6 US GENERAL ANESTHESIA DRUGS MARKET: FINAL CAGR PROJECTIONS (2020−2025)
    2.3 INDUSTRY INSIGHTS
    2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 25)
  FIGURE 7 US GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020 VS. 2025 (USD MILLION)
  FIGURE 8 US GENERAL ANESTHESIA DRUGS MARKET FOR INTRAVENOUS GENERAL ANESTHETICS, BY TYPE, 2020 VS. 2025 (USD MILLION)
  FIGURE 9 US GENERAL ANESTHESIA DRUGS MARKET FOR INHALATIONAL GENERAL ANESTHETICS, BY TYPE, 2020 VS. 2025 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 28)
    4.1 US GENERAL ANESTHESIA DRUGS MARKET OVERVIEW
        FIGURE 10 INCREASING NUMBER OF EMERGENCY SURGERIES AND THE RAPIDLY GROWING AGING POPULATION TO DRIVE MARKET GROWTH
    4.2 US GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2020 VS. 2025
        FIGURE 11 HOSPITALS HOLD THE LARGEST SHARE OF THE US GENERAL ANESTHESIA DRUGS MARKET

5 MARKET OVERVIEW (Page No. - 30)
    5.1 MARKET ANALYSIS
    5.2 MARKET DYNAMICS
        FIGURE 12 US GENERAL ANESTHESIA DRUGS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
           5.2.1 DRIVERS
                    5.2.1.1 Rapid growth in the geriatric population
                    5.2.1.2 Rising prevalence of cancer
                    5.2.1.3 Rising number of emergency surgeries
           5.2.2 RESTRAINTS
                    5.2.2.1 Risks associated with general anesthesia in pediatric patients and pregnant women
                            TABLE 1 LIST OF GENERAL ANESTHETICS AND SEDATION DRUGS AFFECTED BY LABEL CHANGE
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Patent expiry of Lusedra
    5.3 MARKET SIZE
           5.3.1 HISTORICAL MARKET TRENDS, 2016–2019
                 FIGURE 13 US KETAMINE MARKET, 2016–2019 (USD MILLION)
           5.3.2 MARKET FORECASTS, 2020–2025
                 FIGURE 14 US KETAMINE MARKET, 2020–2025 (USD MILLION)
    5.4 IMPACT OF COVID-19 ON THE GROWTH OF THE US GENERAL ANESTHESIA DRUGS MARKET

6 DISTRIBUTION STRUCTURE (Page No. - 35)
    6.1 US KETAMINE MARKET: DISTRIBUTION STRUCTURE
        FIGURE 15 DISTRIBUTION STRUCTURE
        TABLE 2 US: KETAMINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2019 (USD MILLION)
        TABLE 3 US: KETAMINE MARKET, BY DISTRIBUTION CHANNEL, 2020–2025 (USD MILLION)
           6.1.1 US KETAMINE MARKET, BY MANUFACTURER
                 TABLE 4 US: KETAMINE MARKET, BY MANUFACTURER, 2016–2019 (USD MILLION)
                 TABLE 5 US: KETAMINE MARKET, BY MANUFACTURER, 2016–2019 (KILOGRAM)
                 TABLE 6 US: KETAMINE MARKET, BY MANUFACTURER, 2020–2025 (USD MILLION)
                 TABLE 7 US: KETAMINE MARKET, BY MANUFACTURER, 2020–2025 (KILOGRAM)
           6.1.2 US KETAMINE MARKET, BY DISTRIBUTION CHANNEL
                    6.1.2.1 Group purchasing organizations
                            FIGURE 16 US KETAMINE MARKET SHARE, BY GPO (2019)
                            TABLE 8 US: KETAMINE MARKET, BY GPO, 2016–2019 (USD MILLION)
                            TABLE 9 US: KETAMINE MARKET, BY GPO, 2016–2019 (KILOGRAM)
                            TABLE 10 US: KETAMINE MARKET, BY GPO, 2020–2025 (USD MILLION)
                            TABLE 11 US: KETAMINE MARKET, BY GPO, 2020–2025 (KILOGRAM)
                    6.1.2.2 Distributors
                            FIGURE 17 US KETAMINE MARKET SHARE, BY DISTRIBUTOR (2019)
                            TABLE 12 US: KETAMINE MARKET, BY DISTRIBUTOR, 2016–2019 (USD MILLION)
                            TABLE 13 US: KETAMINE MARKET, BY DISTRIBUTOR, 2016–2019 (KILOGRAM)
                            TABLE 14 US: KETAMINE MARKET, BY DISTRIBUTOR, 2020–2025 (USD MILLION)
                            TABLE 15 US: KETAMINE MARKET, BY DISTRIBUTOR, 2020–2025 (KILOGRAM)
    6.2 KEY LEGAL TRENDS FOR CONTROLLED SUBSTANCES
           6.2.1 COMPLIANCE ASSOCIATED WITH THE MANUFACTURING OF NARCOTICS IN THE US
                    6.2.1.1 Registration
                    6.2.1.2 Security
                    6.2.1.3 Labeling and packaging
                    6.2.1.4 Inventory
                    6.2.1.5 Records
           6.2.2 COMPLIANCE ASSOCIATED WITH VENDORS OF NARCOTICS IN THE US
    6.3 PRODUCT CATEGORY ENUMERATION
           6.3.1 KETAMINE
           6.3.2 OTHER BRANDS

7 US GENERAL ANESTHESIA DRUGS MARKET: KEY INFORMATION (Page No. - 46)
    7.1 IMPORT & EXPORT SYSTEMS IN THE US
           7.1.1 IMPORT OF CONTROLLED SUBSTANCES
                    7.1.1.1 Shipment of controlled substances
                    7.1.1.2 Registration of applicants for the import and export of controlled substances
           7.1.2 EXPORT OF CONTROLLED SUBSTANCES
                    7.1.2.1 Exceptions in exportation for special scientific purposes
                    7.1.2.2 Custom tariffs for imports
                            TABLE 16 HARMONIZED TARIFF SCHEDULE FOR ANESTHESIA DRUGS
                            TABLE 17 ANESTHESIA MOLECULES: CHEMICAL ABSTRACTS SERVICES NUMBERS
           7.1.3 TRANSPORT OF CONTROLLED SUBSTANCES
           7.1.4 CUSTOMS CLEARANCE
                 FIGURE 18 CUSTOMS CLEARANCE PROCEDURE FOR IMPORTED CONTROLLED SUBSTANCES IN THE US
                 FIGURE 19 EXPORT CUSTOMS CLEARANCE PROCEDURE FOR CONTROLLED SUBSTANCES IN THE US
           7.1.5 NON-TARIFF BARRIERS
                 TABLE 18 REGULATORY REQUIREMENTS FOR CONTROLLED SUBSTANCES
    7.2 TOP RELATED EXHIBITIONS
        TABLE 19 ANESTHESIA EXHIBITIONS/WORKSHOPS/CONFERENCES IN THE US
    7.3 DESCRIPTION OF POTENTIAL BUYERS
        TABLE 20 POTENTIAL GROUP PURCHASING ORGANIZATIONS
        TABLE 21 POTENTIAL DISTRIBUTORS
        FIGURE 20 BUSINESS STRATEGY

8 PRODUCT ANALYSIS (Page No. - 60)
    8.1 ANESTHESIA DRUGS MARKET SEGMENTATION IN THE US
        FIGURE 21 ANESTHESIA DRUGS MARKET SEGMENTATION
        FIGURE 22 LOCATION QUOTIENT OF ANESTHESIA SPECIALISTS IN THE US, BY STATE (MAY 2019)
        FIGURE 23 ANESTHESIA LANDSCAPE
        TABLE 22 ANESTHESIA DRUGS MARKET, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 23 ANESTHESIA DRUGS MARKET, BY TYPE, 2020–2025 (USD MILLION)
    8.2 GENERAL ANESTHESIA
           8.2.1 INTRODUCTION
           8.2.2 GENERAL ANESTHESIA DRUGS MARKET SEGMENTATION
                 FIGURE 24 SEGMENTATION OF THE GENERAL ANESTHESIA DRUGS MARKET
                 TABLE 24 US: GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2016–2019 (USD MILLION)
                 TABLE 25 US: GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION)
    8.3 INTRAVENOUS GENERAL ANESTHETICS
        TABLE 26 US: INTRAVENOUS GENERAL ANESTHETICS MARKET, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 27 US: INTRAVENOUS GENERAL ANESTHETICS MARKET, BY TYPE, 2020–2025 (USD MILLION)
    8.4 INHALATIONAL GENERAL ANESTHETICS
        TABLE 28 US: INHALATIONAL GENERAL ANESTHETICS MARKET, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 29 US: INHALATIONAL GENERAL ANESTHETICS MARKET, BY TYPE, 2020–2025 (USD MILLION)
           8.4.1 MAJOR BRANDS/MOLECULES
                    8.4.1.1 Propofol
                    8.4.1.2 Benzodiazepines
                    8.4.1.3 Methohexital Sodium
    8.5 COMPETITION IN THE US
        FIGURE 25 PROPERTIES OF INTRAVENOUS ANESTHESIA DRUGS
        FIGURE 26 INTRAVENOUS GENERAL ANESTHETICS MARKET, BY MOLECULE, 2019 (USD MILLION)
           8.5.1 SALES PRICE
                 TABLE 30 PROPOFOL PRICE, 2020 (USD)
                 TABLE 31 MIDAZOLAM PRICE, 2020 (USD)
                 TABLE 32 METHOHEXITAL SODIUM PRICE, 2020 (USD)
                 TABLE 33 ETOMIDATE PRICE, 2020 (USD)
                 TABLE 34 KETAMINE PRICE, 2020 (USD)
           8.5.2 MAJOR BRANDS
                 TABLE 35 GENERAL INTRAVENOUS ANESTHESIA DRUGS: USAGE TRENDS
    8.6 POTENTIAL BUYERS IN THE US
           8.6.1 POTENTIAL BUYERS, BY STATE
                 TABLE 36 GROUP PURCHASING ORGANIZATIONS, BY STATE
                 TABLE 37 DISTRIBUTORS, BY STATE

9 US GENERAL ANESTHESIA DRUGS MARKET, BY END USER (Page No. - 74)
    9.1 INTRODUCTION
        TABLE 38 US: GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2016–2019 (USD MILLION)
        TABLE 39 US: GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2020–2025 (USD MILLION)
           9.1.1 HOSPITALS
                    9.1.1.1 Growing patient pool in hospitals to drive market growth
           9.1.2 AMBULATORY SURGERY CENTERS
                    9.1.2.1 Increasing number of ASCs in the country to boost the market growth

10 COMPETITIVE LANDSCAPE (Page No. - 77)
     10.1 OVERVIEW
     10.2 MARKET SHARE ANALYSIS (2019)
          FIGURE 27 US GENERAL ANESTHESIA DRUGS MARKET SHARE, BY KEY PLAYER, 2019
     10.3 KEY MARKET DEVELOPMENTS
             10.3.1 PRODUCT LAUNCHES
             10.3.2 ACQUISITIONS
             10.3.3 EXPANSIONS
             10.3.4 PARTNERSHIPS

11 COMPANY EVALUATION MATRIX AND COMPANY PROFILES (Page No. - 80)

     11.1 OVERVIEW
     11.2 COMPETITIVE LEADERSHIP MAPPING: MAJOR MARKET PLAYERS (2019)
             11.2.1 STARS
             11.2.2 EMERGING LEADERS
             11.2.3 PERVASIVE PLAYERS
             11.2.4 PARTICIPANTS
                    FIGURE 28 US GENERAL ANESTHESIA DRUGS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019

12 COMPANY PROFILES (Page No. - 82)
(Business Overview, Products Offered, Recent Developments, MnM View)*
     12.1 PFIZER, INC.
          FIGURE 29 PFIZER, INC.: COMPANY SNAPSHOT (2019)
     12.2 FRESENIUS SE & CO. KGAA
          FIGURE 30 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2019)
     12.3 BAXTER INTERNATIONAL INC.
          FIGURE 31 BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT (2019)
     12.4 HIKMA PHARMACEUTICALS PLC
          FIGURE 32 HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2019)
     12.5 ABBVIE
          FIGURE 33 ABBVIE: COMPANY SNAPSHOT (2019)
     12.6 PIRAMAL ENTERPRISES LIMITED
          FIGURE 34 PIRAMAL ENTERPRISES LIMITED: COMPANY SNAPSHOT (2020)
     12.7 ABBOTT LABORATORIES
          FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2019)
     12.8 ASTRAZENECA PLC
          FIGURE 36 ASTRAZENECA PLC: COMPANY SNAPSHOT (2019)
     12.9 NOVARTIS AG
          FIGURE 37 NOVARTIS AG: COMPANY SNAPSHOT (2019)
     12.10 F. HOFFMANN-LA ROCHE LTD.
           FIGURE 38 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2019)
     12.11 BAYER AG
           FIGURE 39 BAYER AG: COMPANY SNAPSHOT (2019)
     12.12 GLAXOSMITHKLINE PLC
           FIGURE 40 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019)
     12.13 GILEAD SCIENCES
           FIGURE 41 GILEAD SCIENCES: COMPANY SNAPSHOT (2019)
     12.14 MERCK & CO., INC.
           FIGURE 42 MERCK & CO., INC.: COMPANY SNAPSHOT (2019)
     12.15 SANOFI
           FIGURE 43 SANOFI: COMPANY SNAPSHOT (2019)
     12.16 PAR PHARMACEUTICAL
     12.17 TEVA PHARMACEUTICALS
     12.18 VIATRIS (MYLAN)
     12.19 HERITAGE PHARMACEUTICALS INC.
     12.20 AKORN
     12.21 APOTEX

*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

13 APPENDIX (Page No. - 112)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE
     13.3 RELATED REPORTS
     13.4 AUTHOR DETAILS

This market research study involved extensive use of secondary sources, directories, and databases to identify and collect important information on the US general anesthesia drugs market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information, and to assess market prospects. The size of the US general anesthesia drugs market was estimated through various secondary research approaches and triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

The secondary sources referred to for this research study include publications from the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), US Food and Drug Administration (FDA), World Bank, World Health Organization (WHO), American Society of Anesthesiologists (ASA), The Association of Anaesthetists, International Anesthesia Research Society, American Association of Nurse Anesthetists, and National Center for Biotechnology Information (NCBI). Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the US general anesthesia drugs market, which was validated through primary research.       

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the US general anesthesia drugs market scenario through secondary research. The primary sources included industry experts from core and related industries and preferred suppliers, manufacturers, distributors, anesthesiologists, doctors, group purchasing organizations (GPOs), alliances, and standards and certification organizations from companies and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, which include key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as to assess future prospects. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

US General Anesthesia Drugs Market  Size, and Share

To know about the assumptions considered for the study,download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (revenue share analysis of leading players) and top-down approach (assessment of utilization/adoption/penetration trends, by route of administration, end user,and company type).

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Objectives

  • To define, describe, and measure the  US general anesthesia drugs market based on route of administration and end user
  • To provide detailed information regarding the major factors, such as drivers, restraints, opportunities  influencing the growth of the market
  • To strategically analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the  US general anesthesia drugs market
  • To analyze the opportunities in the  US general anesthesia drugs market for key stakeholders and provide details of the competitive landscape for major market leaders
  • To forecast the size of the market segments with respect to US
  • To profile the key players and comprehensively analyze their core competencies2 in terms of key developments, product portfolios, and financials
  • To track and analyze competitive developments such as partnerships, agreements, alliances, joint ventures, collaborations, product launches, expansions, acquisitions, grants/funds, and licensing agreements, among others, in the US general anesthesia drugs market
COVID-19

Get in-depth analysis of the COVID-19 impact on the US General Anesthesia Drugs Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the US General Anesthesia Drugs Market

Request For Special Pricing
Report Code
PH 1174
Published ON
Feb, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the US General Anesthesia Drugs Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved